Noopept (N-Phenylacetyl-L-Prolylglycine Ethyl Ester)
Overview
Noopept is a synthetic nootropic compound — the ethyl ester of N-phenylacetyl-L-prolylglycine — designed as a small-molecule mimetic of the endogenous cyclic dipeptide cyclo-L-prolylglycine. Although it sits in this peptide database and has a proline-glycine backbone, it is really a peptide-derived small molecule, not a standard peptide. In research it is studied for cognitive enhancement and neuroprotection via AMPA-receptor modulation and BDNF induction. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 157115-85-0 |
| Class | Dipeptide-derived nootropic (small molecule) |
| Chemical name | N-phenylacetyl-L-prolylglycine ethyl ester |
| Molecular formula | C₁₇H₂₂N₂O₄ |
| Molecular weight | 342.39 g/mol |
| Purity (HPLC) | ≥ 99% |
| Appearance | White crystalline powder |
- Class
- Dipeptide-derived nootropic small molecule
- Design basis
- Mimetic of cyclo-L-prolylglycine
- Research status
- Preclinical and clinical (Russia)
- Study routes
- Oral, sublingual
- Half-life
- ≈ 2–5 h (oral)
- Key feature
- AMPA-receptor facilitation; BDNF induction
Mechanism of Action
Noopept was designed as a mimetic of cyclo-L-prolylglycine, a metabolite linked to the older nootropic piracetam. Its studied action is multimodal: positive modulation of AMPA-type glutamate receptors (supporting synaptic transmission) together with induction of BDNF/NGF and the neuroplasticity signalling that follows.
| Component | Detail |
|---|---|
| Primary target | AMPA-type glutamate receptors (positive modulation) |
| Neurotrophic | Upregulation of BDNF and NGF expression |
| Metabolite | Studied as a mimetic of cyclo-L-prolylglycine |
| Antioxidant | Reported antioxidant / anti-apoptotic effects |
| Cholinergic | Modulation of cholinergic transmission |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 2–5 h (oral) |
| Bioavailability | Oral / sublingual activity |
| Metabolism | Hydrolysis to active metabolites (incl. cycloprolylglycine) |
| Route of administration | Oral, sublingual |
| Elimination | Renal (metabolites) |
Research Evidence
Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Rodent cognition models | Memory consolidation and learning | Noopept preclinical literature |
| Neuroprotection models | Oxidative stress and neuronal survival | Noopept preclinical literature |
| Clinical cognition observation | Mild cognitive impairment research | Noopept clinical literature (Russia) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Improved memory consolidation and learning | rodent cognition | Noopept literature |
| Neuroprotection via AMPA modulation and BDNF induction | neuronal models | Noopept literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Handling Reference
Handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 10–20 mg per dose, in study protocols |
| Solvent (for solutions) | Water / saline (readily soluble) |
| Storage | 2–8°C, protected from light |
| Do not use | If material shows discoloration or degradation |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Tolerability | Well tolerated in reported studies |
| Sedation / stimulation | Generally neither markedly sedating nor stimulating |
| Cytotoxicity | No cytotoxicity reported at studied levels |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White crystalline powder |
| Solubility (water) | Soluble |
| Chemical type | Small molecule (peptide-derived) |
| Stability | Stable refrigerated, protected from light |
Synthesis & Manufacturing
Noopept is made by solution-phase organic synthesis — phenylacetylation of proline, coupling to glycine, and esterification — rather than by solid-phase peptide synthesis, and is characterised by NMR and MS as a small molecule.
- Solution-phase organic synthesis (phenylacetyl-proline → prolylglycine ethyl ester)
- Crystallization / chromatographic purification to ≥ 99%
- Identity confirmed by NMR and mass spectrometry
Analytical Methods
Noopept is a peptide-derived small molecule, so it is characterised by the organic-chemistry panel (NMR, MS, HPLC) rather than by peptide-specific assays. A key attribute is confirming the intact ethyl ester (its main hydrolysis point).
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 210 nm) | Purity | ≥ 99% |
| ¹H / ¹³C NMR | Structure confirmation | Consistent with the phenylacetyl-prolylglycine ethyl ester |
| ESI-MS / HRMS | Identity / accurate mass | [M+H]⁺ ≈ 343 Da |
| IR spectroscopy | Ester / amide confirmation | Characteristic carbonyl bands |
| Melting point | Identity | Sharp, characteristic |
| Chiral HPLC | Confirm L-proline configuration | Single enantiomer |
| Karl Fischer | Water content | Low (per specification) |
| Residual solvents (GC) | ICH Q3C limits | Within limits |
Representative HPLC method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase: aqueous buffer / acetonitrile gradient · Flow rate: 1.0 mL/min
- Detection: UV 210 nm · Identity confirmed by NMR + HRMS; chirality by chiral HPLC
Stability Data
| Condition | Duration | Result |
|---|---|---|
| Solid, 2–8°C, dry, dark | ≥ 36 months | Stable |
| Solid, room temperature, dry | ≥ 24 months | Stable |
| Solid, 40°C (accelerated) | 3 months | No significant degradation |
| Aqueous solution, 2–8°C | ≈ 2 weeks | Slow ester hydrolysis |
| Aqueous solution, 25°C | Days | Faster ester hydrolysis — prepare fresh |
| Photostability (ICH Q1B) | Standard | Low light sensitivity |
- As a solid it is very stable when kept dry and cold.
- In solution the ethyl ester slowly hydrolyses (to the acid / cycloprolylglycine metabolite), so prepare working solutions fresh and keep them cold.
Selected References
- Noopept (GVS-111) nootropic and neuroprotection research literature.
- Reviews of proline-containing dipeptide nootropics and cycloprolylglycine.
Quality & Supply
- HPLC ≥ 99% purity with a Certificate of Analysis per batch
- Identity confirmed by NMR and mass spectrometry
- Research quantities through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Noopept — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
